BIMI International Medical Inc. (BIMI)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2022 | 11.83 Million USD | -56.31% |
| 2021 | 27.07 Million USD | 110.82% |
| 2020 | 12.84 Million USD | 8030.82% |
| 2019 | 157.97 Thousand USD | -97.59% |
| 2018 | 6.54 Million USD | -23.11% |
| 2017 | 8.5 Million USD | 40.83% |
| 2016 | 6.04 Million USD | -10.03% |
| 2015 | 6.71 Million USD | -32.72% |
| 2014 | 9.98 Million USD | 75.88% |
| 2013 | 5.67 Million USD | -38.78% |
| 2012 | 9.26 Million USD | -37.91% |
| 2011 | 14.92 Million USD | -41.16% |
| 2010 | 25.37 Million USD | 24.84% |
| 2009 | 20.32 Million USD | 28.35% |
| 2008 | 15.83 Million USD | 53.2% |
| 2007 | 10.33 Million USD | 96.17% |
| 2006 | 5.26 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 500.00 USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q1 | 3.19 Million USD | 158.87% |
| 2023 Q2 | 5.55 Million USD | 73.81% |
| 2023 Q3 | 2.52 Million USD | -54.6% |
| 2022 Q4 | -5.43 Million USD | -174.25% |
| 2022 FY | 11.83 Million USD | -56.31% |
| 2022 Q3 | 7.31 Million USD | 158.56% |
| 2022 Q1 | 5.01 Million USD | 167.39% |
| 2022 Q2 | 2.82 Million USD | -43.64% |
| 2021 Q2 | 9.25 Million USD | 326.98% |
| 2021 Q1 | 2.16 Million USD | -60.78% |
| 2021 FY | 27.07 Million USD | 110.82% |
| 2021 Q3 | 13.77 Million USD | 48.83% |
| 2021 Q4 | 1.87 Million USD | -86.37% |
| 2020 Q1 | 426.89 Thousand USD | 144.34% |
| 2020 Q3 | 3.09 Million USD | -18.46% |
| 2020 Q4 | 5.52 Million USD | 78.82% |
| 2020 FY | 12.84 Million USD | 8030.82% |
| 2020 Q2 | 3.79 Million USD | 788.0% |
| 2019 Q1 | 578.71 Thousand USD | -87.76% |
| 2019 FY | 157.97 Thousand USD | -97.59% |
| 2019 Q4 | -962.82 Thousand USD | -562.0% |
| 2019 Q3 | 208.4 Thousand USD | -37.55% |
| 2019 Q2 | 333.69 Thousand USD | -42.34% |
| 2018 FY | 6.54 Million USD | -23.11% |
| 2018 Q1 | 147.07 Thousand USD | -96.84% |
| 2018 Q2 | 564.33 Thousand USD | 283.7% |
| 2018 Q3 | 1.1 Million USD | 95.4% |
| 2018 Q4 | 4.72 Million USD | 328.78% |
| 2017 FY | 8.5 Million USD | 40.83% |
| 2017 Q2 | 1.67 Million USD | 61.91% |
| 2017 Q1 | 1.03 Million USD | -56.77% |
| 2017 Q3 | 1.14 Million USD | -31.92% |
| 2017 Q4 | 4.65 Million USD | 307.45% |
| 2016 Q2 | 683.75 Thousand USD | -56.19% |
| 2016 FY | 6.04 Million USD | -10.03% |
| 2016 Q1 | 1.56 Million USD | -2.63% |
| 2016 Q4 | 2.39 Million USD | 71.14% |
| 2016 Q3 | 1.4 Million USD | 104.8% |
| 2015 Q1 | 1.18 Million USD | -68.0% |
| 2015 Q3 | 2.62 Million USD | 100.14% |
| 2015 FY | 6.71 Million USD | -32.72% |
| 2015 Q4 | 1.6 Million USD | -38.85% |
| 2015 Q2 | 1.3 Million USD | 10.89% |
| 2014 Q1 | 1.74 Million USD | 11.76% |
| 2014 FY | 9.98 Million USD | 75.88% |
| 2014 Q2 | 1.59 Million USD | -8.66% |
| 2014 Q4 | 3.69 Million USD | 25.36% |
| 2014 Q3 | 2.94 Million USD | 84.29% |
| 2013 Q2 | 1.47 Million USD | 13.61% |
| 2013 Q3 | 1.33 Million USD | -9.45% |
| 2013 Q4 | 1.56 Million USD | 17.14% |
| 2013 Q1 | 1.29 Million USD | -57.01% |
| 2013 FY | 5.67 Million USD | -38.78% |
| 2012 Q3 | 1.74 Million USD | -47.09% |
| 2012 FY | 9.26 Million USD | -37.91% |
| 2012 Q4 | 3.02 Million USD | 72.85% |
| 2012 Q1 | 1.19 Million USD | -75.21% |
| 2012 Q2 | 3.3 Million USD | 175.59% |
| 2011 Q3 | 2.59 Million USD | -46.92% |
| 2011 Q1 | 2.61 Million USD | -64.02% |
| 2011 FY | 14.92 Million USD | -41.16% |
| 2011 Q4 | 4.83 Million USD | 86.38% |
| 2011 Q2 | 4.88 Million USD | 86.83% |
| 2010 FY | 25.37 Million USD | 24.84% |
| 2010 Q1 | 2.84 Million USD | -44.51% |
| 2010 Q2 | 7.21 Million USD | 154.11% |
| 2010 Q3 | 8.04 Million USD | 11.46% |
| 2010 Q4 | 7.26 Million USD | -9.66% |
| 2009 Q1 | 2.41 Million USD | -40.57% |
| 2009 Q2 | 5.21 Million USD | 115.66% |
| 2009 Q3 | 7.56 Million USD | 44.99% |
| 2009 Q4 | 5.11 Million USD | -32.35% |
| 2009 FY | 20.32 Million USD | 28.35% |
| 2008 Q1 | 2.86 Million USD | -12.5% |
| 2008 Q4 | 4.07 Million USD | -11.52% |
| 2008 Q3 | 4.6 Million USD | 7.11% |
| 2008 Q2 | 4.29 Million USD | 49.97% |
| 2008 FY | 15.83 Million USD | 53.2% |
| 2007 Q4 | 3.27 Million USD | 61.2% |
| 2007 Q2 | 4.02 Million USD | 301.89% |
| 2007 Q1 | 1 Million USD | 0.0% |
| 2007 FY | 10.33 Million USD | 96.17% |
| 2007 Q3 | 2.03 Million USD | -49.59% |
| 2006 Q2 | 2.01 Million USD | 7988.9% |
| 2006 Q3 | 1.93 Million USD | -4.05% |
| 2006 Q4 | - USD | -100.0% |
| 2006 FY | 5.26 Million USD | 0.0% |
| 2006 Q1 | 24.96 Thousand USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q2 | - USD | -100.0% |
| 2002 FY | 500.00 USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q1 | 500.00 USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | - USD | -Infinity% |
| China Jo-Jo Drugstores, Inc. | 154.54 Million USD | 92.345% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 130.19 Million USD | 90.913% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 130.19 Million USD | 90.913% |
| Leafly Holdings, Inc. | 42.25 Million USD | 72.0% |
| Leafly Holdings, Inc. | 42.25 Million USD | 72.0% |
| LifeMD, Inc. | 152.54 Million USD | 92.245% |
| LifeMD, Inc. | 152.54 Million USD | 92.245% |
| TRxADE HEALTH, Inc. | 8.27 Million USD | -43.013% |
| PetMed Express, Inc. | 281.06 Million USD | 95.791% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.992% |